Literature DB >> 17516214

The expanded double negative T cell populations of a patient with ALPS are not clonally related to CD4+ or to CD8+ T cells.

Arnold Marlies1, Gaipl Udo, Brunner Juergen, Spriewald Bernd, Martin Herrmann, Johannes Peter Haas.   

Abstract

The autoimmune lymphoproliferative syndrome (ALPS) is characterized by non-malignant lymphoproliferation and signs of autoimmunity. A hallmark of ALPS are high amounts of circulating CD3+/CD4-/CD8- double negative T-lymphocytes (DN T cells). The origin of these cells remains elusive. To investigate the relationships of DN T cells and the single positive T cell populations (CD4+ and CD8+), we analyzed by spectratyping the complementarity determining regions 3 (CDR3) of the T cell receptors in sorted "single positive" (CD4+, CD8+) and DN T cells in a patient with ALPS type 1a. We observed signs for clonal expansion in all three T cell subpopulations. Strong and weak clonal expansions were to be seen in 16 and 14 for DN, 6 and 12 for CD8+, and 1 and 5 for CD4 + T cells, respectively. Most importantly, 24 out of 30 aberrant peaks in the spectratype histograms of the DN T cells where unique for this population and were not to be detected in the histograms of the single positive T cells. In contrast to published data, we conclude that expanded DN T cell populations in ALPS are not generally derived from expanded CD3+/CD4+ or CD3+/CD8+ populations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17516214     DOI: 10.1080/08916930701356473

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  6 in total

1.  Extreme lymphoproliferative disease and fatal autoimmune thrombocytopenia in FasL and TRAIL double-deficient mice.

Authors:  Lisa M Sedger; Arna Katewa; Ann K Pettersen; Sarah R Osvath; Geoff C Farrell; Graeme J Stewart; Linda J Bendall; Stephen I Alexander
Journal:  Blood       Date:  2010-02-25       Impact factor: 22.113

Review 2.  HEM1 Actin Immunodysregulatory Disorder: Genotypes, Phenotypes, and Future Directions.

Authors:  Sarah Cook; Michael J Lenardo; Alexandra F Freeman
Journal:  J Clin Immunol       Date:  2022-07-22       Impact factor: 8.542

Review 3.  Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS).

Authors:  David T Teachey; Alix E Seif; Stephan A Grupp
Journal:  Br J Haematol       Date:  2009-11-23       Impact factor: 6.998

4.  Targeting Notch signaling in autoimmune and lymphoproliferative disease.

Authors:  David T Teachey; Alix E Seif; Valerie I Brown; Marlo Bruno; Ralph M Bunte; Yueh J Chang; John K Choi; Jonathan D Fish; Junior Hall; Gregor S Reid; Theresa Ryan; Cecilia Sheen; Patrick Zweidler-McKay; Stephan A Grupp
Journal:  Blood       Date:  2007-10-09       Impact factor: 22.113

5.  Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS).

Authors:  Seiji Yokoyama; Pin-Yu Perera; Seigo Terawaki; Nobumasa Watanabe; Osamu Kaminuma; Thomas A Waldmann; Takachika Hiroi; Liyanage P Perera
Journal:  J Clin Immunol       Date:  2015-10-09       Impact factor: 8.317

6.  Lymphocytic profiling in thyroid cancer provides clues for failure of tumor immunity.

Authors:  Shahnawaz Imam; Rodis Paparodis; Deepak Sharma; Juan Carlos Jaume
Journal:  Endocr Relat Cancer       Date:  2014-03-12       Impact factor: 5.678

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.